<DOC>
	<DOCNO>NCT01855048</DOCNO>
	<brief_summary>The Objectives study evaluate safety , pharmacokinetics pharmacodynamics single dose N-Rephasin® SAL200 healthy male subject .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics Pharmacodynamics N-Rephasin® SAL200 Healthy Male Volunteers</brief_title>
	<detailed_description>The purpose study evaluate pharmacokinetics , pharmacodynamics safety experimental intravenous medication , N-Rephasin® SAL200 healthy male . Participants include 36 male volunteer . Participants group accord dosage N-Rephasin® SAL200 include placebo ( 0 mg/kg ) . Study procedures include : check vital sign , report experienced side effect , physical examination include assessment cardiovascular system , blood sample collection monitoring pharmacokinetics , pharmacodynamics antibody production etc . Participants involve study related procedure 50 day injection .</detailed_description>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<criteria>Healthy male subject whose age 20 ~ 45 time screen visit . Body weight ≥50kg &lt; 90kg , within ±20 % ideal body weight . [ ideal body weight ( kg ) = { height ( cm ) 100 } x 0.9 ] Subject agree participate trial follow trialrelated rule full understanding , full account trial Present disease ( ) medical history ( y ) ( ) clinically significant liver , heart , nervous system , respiratory system , haematooncology , cardiovascular psychopathy . Diagnosed suspect infectious disease within 30 day prior administration . Clinically significantly allergic drug ( ) contain AI NRephasin® SAL200 drug include aspirin antibiotic , medical history ( y ) allergy . Already take drug ( ) contain AI NRephasin® SAL200 . Positive Antibody NRephasin® SAL200 . SBP≤90mmHg DBP≤50mmHg , otherwise , SBP≥150mmHg DBP≥100mmHg Vital sign measure take 3 minute rest sit position . Has medical history drug abuse positive drug abuse urine drug screening . Has take prescription drug ( ) herbal medicine ( ) within 14 day prior administration , otherwise , OTC ( Over counter ) ( ) vitamin ( ) within 7 day prior administration ( However , participate study investigator make decision subject participate regardless drug take ) . Has take study drug within 2 month prior administration . Has donate blood ( whole blood donation component transfusion ) within ( 2 month 1 month , respectively ) prior administration , otherwise , receive blood transfusion within 1 month prior administration . Smoke present positive metabolism nicotine urine test . Drink regularly ( 21 units/week , 1 unit= 10 g pure alcohol ) , otherwise , able interrupt drinking smoking study period . Investigator make decision subject eligible base result laboratory test reason . Not agree contraception 60days administration , otherwise , notification pregnancy case partner pregnant 90 day administration .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>N-Rephasin® SAL200</keyword>
	<keyword>endolysin</keyword>
	<keyword>Placebo</keyword>
</DOC>